NeuroPace Inc Dossier
Qualitative Analysis
Business overview
NeuroPace, Inc. (NASDAQ: NPCE) is a commercial-stage medical device company focused on transforming the lives of people living with drug-resistant epilepsy. The company's flagship product, the RNSu0000 System, is the first and only commercially available, closed-loop, brain-responsive neuromodulation platform that delivers personalized, real-time electrical stimulation directly at the seizure source. By continuously monitoring brain waves, recognizing unique seizure onset signatures, and responding in real time, the RNS System prevents seizures before they manifest, significantly improving patient quality of life.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Deepening adoption and utilization of the RNS System within Level 4 Comprehensive Epilepsy Centers (CECs) by increasing active prescribers, accounts, and patient pipeline.
Expected impact: Aims to drive core RNS revenue growth of 21% to 23% in 2026.
Enhancing education and referral pathways from community neurology practices to Level 4 CECs to capture patients earlier in their treatment journey.
Expected impact: Expands the active patient pipeline and establishes referral pathways that will also support future indication expansions.
Developing and launching AI-powered software tools, such as SeizureID and NeuroPace AI, alongside a next-generation device platform to improve physician efficiency and patient care.
Expected impact: Enhances the clinical and workflow value proposition of the RNS System, transitioning it from a hardware device to a data-driven therapy platform.
Winding down the SEEG product distribution relationship with DIXI Medical, including selling back remaining inventory at cost, to focus exclusively on high-margin core neuromodulation.
Expected impact: Improves overall gross margins and allows management to focus resources entirely on the high-margin RNS business.